Equillium, Inc., founded in 2017, has yet to bring any products to market, focusing primarily on the clinical development of two novel candidates, EQ504 and EQ302. Despite sustained operating losses that deepened in 2025, the company successfully raised capital via a 2025 private placement to propel its pivotal Phase 1 trial for EQ504. The company’s near-term growth hinges on clinical milestones and regulatory approvals, with significant risks tied to funding availability, regulatory hurdles, and operational dependencies on third-party contractors. Equillium’s capital position remains sufficient for now but limited operating cash flows and continued losses underscore ongoing financial constraints.